Lankenau Institute for Medical Research (LIMR), the research division of Main Line Health, will manage and commercialize several of its biomedical and healthcare inventions through a recently initiated agreement with the Office of Innovation at Thomas Jefferson University (Jefferson).
In addition to conducting biomedical research, LIMR’s resident faculty develop new biopharmaceutical and medical device technologies, particularly in the areas of cancer prevention, prognosis and treatment. Jefferson will assist LIMR in the licensing and commercialization of its growing patent portfolio.
“We’re excited to work with the innovation and technology-transfer experts at Jefferson to help us license selected parts of our portfolio of inventions to the biotechnology and pharmaceutical industries,” said George Prendergast, PhD, president and CEO of LIMR. “In recent years, we have expanded the number of unique technologies developed by our faculty. We look forward to working with our Jefferson colleagues to find partners to help us further develop those innovations so that they can progress to a clinic setting.”
Jefferson has licensed more than 100 inventions and started more than 25 new ventures that have gone on to raise investments of well over $200M to date. Ranked the fifth most innovative university in the North Region by U.S. News & World Report in 2018, Jefferson is considered a national leader in the development and translation of novel medical technology.
“Jefferson is honored to have been selected to partner with LIMR on the translation of its world-class medical research and innovations, and we are very much looking forward to this partnership,” said Dr. Rose Ritts, chief innovation officer and executive vice president of innovation at Jefferson.
The full list of LIMR-developed IP and technologies available for licensing is posted on the LIMR website at mainlinehealth.org/limrtech.